Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

NCT07486934 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Myotonic Dystrophy Type 1 (DM1)
DM1
Myotonic Dystrophy
Steinert Disease
Steinert

Interventions

DRUG: zeleciment basivarsen (DYNE-101)
DRUG: Placebo

Sponsor

Dyne Therapeutics